Skip to main content

14.02.2024 | Review

Global Hepatitis C Virus Elimination — Where Are We?

verfasst von: Mohamed Abdallah, Imam Waked, Mohamed El-Kassas

Erschienen in: Current Hepatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The study aims to provide an overview of hepatitis C virus (HCV) elimination strategies and actions to show the progression of elimination efforts and path to elimination criteria globally. Additionally, we will highlight barriers and challenges facing global elimination actions and propose recommendations to achieve this goal.

Recent Findings

Significant advancements have been made in the field of HCV treatment with the introduction of oral direct-acting antivirals. In 2016, the World Health Organization launched a global health sector strategy to eliminate viral hepatitis by 2030. Over the recent years, many countries have begun to establish and support their national hepatitis programs, trying to fulfill the criteria of complete elimination or the path to elimination, or in other words, to accomplish all requirements to announce viral hepatitis elimination.

Summary

Over the past decade, many countries have improved their progress toward achieving the goal of HCV elimination. Egypt was the first country to receive the “path to elimination certificate.” Other countries from various WHO regions are currently working toward this goal.
Literatur
2.
3.
6.
Zurück zum Zitat Kaplan DE, Serper M, Kaushik A, Durkin C, Raad A, El-Moustaid F, et al. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. J Manag Care Spec Pharm. 2022;28(10):1138–48.PubMed Kaplan DE, Serper M, Kaushik A, Durkin C, Raad A, El-Moustaid F, et al. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. J Manag Care Spec Pharm. 2022;28(10):1138–48.PubMed
7.
Zurück zum Zitat O’ Kane R, Hathorn E. Hepatitis C: recent advances and practical management. Frontline Gastroenterol. 2023;14(5):415–21.CrossRefPubMed O’ Kane R, Hathorn E. Hepatitis C: recent advances and practical management. Frontline Gastroenterol. 2023;14(5):415–21.CrossRefPubMed
9.
Zurück zum Zitat Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep. 2019;1(2):81–9.CrossRefPubMedPubMedCentral Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep. 2019;1(2):81–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hassany M, Abdel-Razek W, AbdAllah M. WHO awards Egypt with gold tier status on the path to eliminate hepatitis C. Lancet Gastroenterol Hepatol. 2023;S2468–1253(23):00364–73. Hassany M, Abdel-Razek W, AbdAllah M. WHO awards Egypt with gold tier status on the path to eliminate hepatitis C. Lancet Gastroenterol Hepatol. 2023;S2468–1253(23):00364–73.
14.
Zurück zum Zitat Wedemeyer H, Tergast TL, Lazarus JV, Razavi H, Bakoyannis K, Baptista-Leite R, et al. Securing wider EU commitment to the elimination of hepatitis C virus. Liver Int Off J Int Assoc Study Liver. 2023;43(2):276–91. Wedemeyer H, Tergast TL, Lazarus JV, Razavi H, Bakoyannis K, Baptista-Leite R, et al. Securing wider EU commitment to the elimination of hepatitis C virus. Liver Int Off J Int Assoc Study Liver. 2023;43(2):276–91.
15.
Zurück zum Zitat Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020;72(4):680–7.CrossRefPubMed Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020;72(4):680–7.CrossRefPubMed
16.
Zurück zum Zitat Pol S, Lair-Mehiri L, Vallet-Pichard A. Is elimination of HCV realistic by 2030: France. Liver Int Off J Int Assoc Study Liver. 2021;41(Suppl 1):45–9. Pol S, Lair-Mehiri L, Vallet-Pichard A. Is elimination of HCV realistic by 2030: France. Liver Int Off J Int Assoc Study Liver. 2021;41(Suppl 1):45–9.
17.
Zurück zum Zitat Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the elimination of viral hepatitis in Zimbabwe: a review of the policies, strategies and challenges. J Viral Hepat. 2021;28(7):994–1002.CrossRefPubMedPubMedCentral Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the elimination of viral hepatitis in Zimbabwe: a review of the policies, strategies and challenges. J Viral Hepat. 2021;28(7):994–1002.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Alaama AS, Khattabi H, Mugisa B, Atta H, Hermez J, Hutin YJ. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019. Lancet Gastroenterol Hepatol. 2022;7(9):862–70.CrossRefPubMed Alaama AS, Khattabi H, Mugisa B, Atta H, Hermez J, Hutin YJ. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019. Lancet Gastroenterol Hepatol. 2022;7(9):862–70.CrossRefPubMed
19.
Zurück zum Zitat Le LV, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, et al. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: results from modelling and global reporting. Liver Int Off J Int Assoc Study Liver. 2022;42(9):1930–4. Le LV, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, et al. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: results from modelling and global reporting. Liver Int Off J Int Assoc Study Liver. 2022;42(9):1930–4.
20.
Zurück zum Zitat Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, et al. Securing sustainable funding for viral hepatitis elimination plans. Liver Int Off J Int Assoc Study Liver. 2020;40(2):260–70. Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, et al. Securing sustainable funding for viral hepatitis elimination plans. Liver Int Off J Int Assoc Study Liver. 2020;40(2):260–70.
21.
Zurück zum Zitat Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533–42.CrossRefPubMedPubMedCentral Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533–42.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. Lancet Glob Health. 2019;7(9):e1180–8.CrossRefPubMed Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. Lancet Glob Health. 2019;7(9):e1180–8.CrossRefPubMed
24.
Zurück zum Zitat Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int Off J Int Assoc Study Liver. 2020;40(3):522–9. Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int Off J Int Assoc Study Liver. 2020;40(3):522–9.
26.
Zurück zum Zitat Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–92.CrossRefPubMed Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–92.CrossRefPubMed
27.
Zurück zum Zitat Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.CrossRef Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.CrossRef
28.
Zurück zum Zitat Matičič M, Lombardi A, Mondelli MU, Colombo M. Elimination of hepatitis C in Europe: can WHO targets be achieved? Clin Microbiol Infect. 2020;26(7):818–23.CrossRefPubMed Matičič M, Lombardi A, Mondelli MU, Colombo M. Elimination of hepatitis C in Europe: can WHO targets be achieved? Clin Microbiol Infect. 2020;26(7):818–23.CrossRefPubMed
30.
Zurück zum Zitat • Taha G, Ezra L, Abu-Freha N. Hepatitis C elimination: opportunities and challenges in 2023. Viruses. 2023;15(7):1413 This article provides a report for HCV elimination efforts and the race for achieving HCV elimination goal.CrossRefPubMedPubMedCentral • Taha G, Ezra L, Abu-Freha N. Hepatitis C elimination: opportunities and challenges in 2023. Viruses. 2023;15(7):1413 This article provides a report for HCV elimination efforts and the race for achieving HCV elimination goal.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Abd Allah M, Wahed S, Ammar I, Kamal E, Alboraie M, Abdel-Razek W, et al. Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources. Liver Int Off J Int Assoc Study Liver. 2021;41(8):1979–80. Abd Allah M, Wahed S, Ammar I, Kamal E, Alboraie M, Abdel-Razek W, et al. Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources. Liver Int Off J Int Assoc Study Liver. 2021;41(8):1979–80.
32.
Zurück zum Zitat Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Björnsson ES, et al. Treatment as Prevention for Hepatitis C (TraP Hep C) — a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283(5):500–7.CrossRefPubMed Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Björnsson ES, et al. Treatment as Prevention for Hepatitis C (TraP Hep C) — a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283(5):500–7.CrossRefPubMed
33.
Zurück zum Zitat Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e673–83.CrossRefPubMed Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e673–83.CrossRefPubMed
34.
Zurück zum Zitat Elsharkawy A, Samir R, Abdallah M, Hassany M, El-Kassas M. The implications of the COVID-19 pandemic on hepatitis B and C elimination programs in Egypt: current situation and future perspective. Egypt Liver J. 2023;13(1):50.CrossRef Elsharkawy A, Samir R, Abdallah M, Hassany M, El-Kassas M. The implications of the COVID-19 pandemic on hepatitis B and C elimination programs in Egypt: current situation and future perspective. Egypt Liver J. 2023;13(1):50.CrossRef
Metadaten
Titel
Global Hepatitis C Virus Elimination — Where Are We?
verfasst von
Mohamed Abdallah
Imam Waked
Mohamed El-Kassas
Publikationsdatum
14.02.2024
Verlag
Springer US
Erschienen in
Current Hepatology Reports
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00655-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.